Aaron Goodman: Is giving Daratumumab to asymptomatic patients better than waiting until they develop cancer?
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared a post on X:
“I have done this poll many times. This is the highest amount who have stated they will treat smoldering myeloma with Daratumumab. Still not the majority.
I am not convinced. I need to know if giving Daratumumab to asymptomatic patients is better than waiting until they develop cancer.
This trial did not answer that question. It showed giving Daratumumab delays time to mainly developing asymptomatic SLiM myeloma (no fractures, no bad renal failure).
It did show OS advantage that was modest, but had everyone in control got Daratumumab at relapse at some point. I don’t know if OS would be true.”
Oncology Poll.
We now have a randomized trial showing Daratumumab improves OS and delays progression.
As an oncologist are you going to start treating high risk smoldering myeloma or are you not convinced yet?
More posts featuring Aaron Goodman.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023